Increase of number of shares and votes in Hansa Biopharma AB (publ)

28 Feb 2019, 16:30

Regulatory information

Lund, Sweden, February 28, 2019 – Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the Company’s number of shares and votes has changed as a result of a new issue of 50,000 ordinary shares carried out in February. The new issue was carried out as part of the completion of the Company’s warrant program 2015-2019. In addition, the Company has converted 3,075 C shares into ordinary shares under Hansa’s long-term incentive programme.

As of February 28, 2019, the total number of registered and outstanding shares of Hansa amounts to 40,731,654 of which 40,026,107 are ordinary shares, together carrying 40,026,107 votes, and 705,547 are C shares, together carrying 70,554.7 votes. The total number of votes in Hansa is 40,096,661.7.

This is information that Hansa Biopharma AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 4:30pm CET on February 28, 2019.

Files

Increase of number of shares and votes in Hansa Biopharma AB (publ)

For further information, please contact:

Company:
Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Biopharma AB (publ)
Mobile: +46 707 175477
E-mail: emanuel.bjorne@hansabiopharma.com

Swedish Investor and Media Relations:
Cord Communications
Mikael Widell
+46 70-311 99 60

U.K. Investor and Media Relations
FTI Consulting
Simon Conway/ Stephanie Cuthbert
+44 (0)20 3727 1000

U.S. Investor and Media Relations:
Argot Partners
Stephanie Marks / David Rosen (media)
+1 212 600 1902

About Hansa Biopharma
Hansa Biopharma AB (NASDAQ Stockholm:HNSA) is harnessing its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions and cancer. The Company’s lead product, imlifidase, is a unique antibody-degrading enzyme in late-stage clinical development to enable kidney transplantation in highly sensitized patients, with additional clinical studies in acute autoimmune indications. Hansa’s research and development program is advancing the next generation of the Company’s technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden.